Shattuck Labs, Inc. Increase (Decrease) in Contract with Customer, Liability
Shattuck Labs, Inc. (STTK) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-08-14
- Shattuck Labs, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Shattuck Labs, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was $0.00.
- Shattuck Labs, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was $3.77M, a 371.13% increase year-over-year.
- Shattuck Labs, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was -$1.11M.
- Shattuck Labs, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $343.00K.
- Shattuck Labs, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $0.00.
- Shattuck Labs, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$29.03M, a 541.99% decline from fiscal 2020.
- Shattuck Labs, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was $6.57M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | |||
| 2024-06-30 | $3.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.65M 10-Q · filed 2025-08-14 | $2.94M derived: sum of 3 quarters · filed 2025-08-14 | $2.25M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.11M 10-Q · filed 2025-05-01 | -$829.00K derived: sum of 2 quarters · filed 2025-05-01 | -$1.51M derived: sum of 3 quarters · filed 2025-05-01 | -$715.00K derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $286.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$400.00K derived: sum of 2 quarters · filed 2024-02-29 | $400.00K derived: sum of 3 quarters · filed 2024-08-01 | $343.00K 10-K · filed 2024-02-29 |
| 2023-09-30 | -$686.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $114.00K derived: sum of 2 quarters · filed 2024-08-01 | $57.00K 10-Q · filed 2023-11-09 | -$159.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $743.00K 10-Q · filed 2024-08-01 | $527.00K derived: sum of 3 quarters · filed 2024-08-01 | $532.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$57.00K 10-Q · filed 2024-05-02 | -$273.00K derived: sum of 2 quarters · filed 2024-05-02 | -$268.00K derived: sum of 3 quarters · filed 2024-05-02 | -$57.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$216.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$211.00K derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2022-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $216.00K derived: sum of 2 quarters · filed 2023-11-09 | $216.00K 10-Q · filed 2023-11-09 | -$29.86M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $211.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $211.00K 10-Q · filed 2023-08-10 | -$29.87M derived: sum of 3 quarters · filed 2023-08-10 | -$31.78M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | -$30.08M derived: sum of 2 quarters · filed 2023-05-09 | -$31.99M derived: sum of 3 quarters · filed 2023-05-09 | -$27.75M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$30.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$31.99M derived: sum of 2 quarters · filed 2023-02-23 | -$27.75M derived: sum of 3 quarters · filed 2023-02-23 | -$29.03M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.33M derived: sum of 2 quarters · filed 2022-11-09 | $1.04M 10-Q · filed 2022-11-09 | $1.74M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $4.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.96M 10-Q · filed 2022-08-11 | $3.66M derived: sum of 3 quarters · filed 2022-08-11 | $3.06M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$1.29M 10-Q · filed 2022-05-12 | -$589.00K derived: sum of 2 quarters · filed 2022-05-12 | -$1.18M derived: sum of 3 quarters · filed 2022-05-12 | $8.09M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $699.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $105.00K derived: sum of 2 quarters · filed 2022-03-15 | $9.38M derived: sum of 3 quarters · filed 2022-03-15 | $6.57M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$594.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $8.68M derived: sum of 2 quarters · filed 2021-11-09 | $5.87M 10-Q · filed 2021-11-09 | $3.05M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $9.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $6.46M 10-Q · filed 2021-08-12 | $3.64M derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$2.81M 10-Q · filed 2021-05-10 | -$5.63M derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | -$2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$2.97M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | -$146.00K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |